



GENFIT-Sanofi research collaboration: achievement of the first step towards treatment for metabolic diseases

Paris (France), Lille (France), Cambridge (Massachusetts, United States) – April 11th, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) and GENFIT (Alternext: ALGFT; ISIN: FR0004163111), today announce the activity of several selected chemical series on a target implicated in multiple metabolic disorders.

This is the first major achievement of the research collaboration signed in March 2011 for a period of three years, during which Sanofi and GENFIT are committed to work together on the discovery and development of new drug candidates.

The announcement lays the first scientific foundation for one of the approaches of this research program targeting mitochondrial dysfunction. The results confirm the hypothesis, formulated in early 2011 on the basis of clinical observations, that the adaptation to stress of cellular mechanisms regulating energy production offers a therapeutic potential in numerous pathologies including metabolic diseases.

In accordance with the terms of the contract, whereby Sanofi obtained the exclusive worldwide rights to develop and commercialize the molecules arising from the research collaboration, GENFIT has received the first of the milestone payments included in the collaboration and licensing agreement. Depending on the preclinical and clinical development, and subsequent registration and commercialization of resulting products, the total of the milestone payments included in the agreement could reach \$54.5 million (€39 million), in addition to royalties from future sales of products developed by Sanofi and resulting from the collaboration.

Jean-François Mouney, Chairman and Chief Executive Officer of GENFIT, declared: *“We are delighted that, following the profiling of hit compounds that are active on the identified target, several chemical series meet the very strict selection criteria that we fixed in collaboration with Sanofi. The relevance of sharing the research activities between our two companies, based on a mutual knowledge resulting from 10 years of collaboration, benefits in this new alliance, and allows hoping for next successes.”*

“The activity tests performed on these molecules offer very interesting perspectives at this stage. We are eager for them to be confirmed by the ongoing optimization procedure that will validate the « Hit to Lead » step of the scientific program,” commented Jean-Marc Herbert, Vice-President, Early to Candidate, Sanofi.



About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments, and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, to address these major public health concerns and their unmet medical needs. GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb for NASH, a hepatic complication of diabetes.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111).

www.genfit.com

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Contacts

Sanofi :

Frédéric LEMONDE-SAN

Tel : 01 53 77 91 55

frederic.lemonde@sanofi.com

Website: www.sanofi.fr

GENFIT :

Jean-François Mouney, CEO & Chairman
of the Management Board

Tel : +33 3 2016 4000

MILESTONES – Press Relations

Bruno Arabian

Tel : +33 (0)1 75 44 87 40

Mobile : +33 (0)6 87 88 47 26

barabian@milestones.fr